Ipca Laboratories: muted Q3FY23, dragged by lower API growth
Ipca Laboratories stock price was down 5% after a lackluster December Quarter FY22 results. While the net profit halved, operating margins tumbled more than eight percentage points in Q3FY23. The company is one of the largest manufacturers and suppliers of active pharmaceutical ingredients (APIs) in the world for over a dozen APIs. Ipca Labs manufactures […]
Continue Reading